Kaposi Sarcoma is a type of cancer in the lining of blood and lymph vessels, typically linked to weakened immune systems. As such, the risk of Kaposi Sarcoma (KS) remains markedly increased up to 800-fold in People Living with Human Immunodeficiency Virus (PLWH), including in the era of effective antiretroviral therapy.
Leadership
The overall goals of the Kaposi's Sarcoma Working Group include to:
- Identify effective, non-toxic and convenient therapies in both the U.S. and globally
- Manage complications and palliative symptoms of Kaposi's Sarcoma
- Define prognostic and predictive biomarkers for Kaposi's Sarcoma
- Define the most quantitative measurements to assess response to systemic and/or local therapy and clinical benefit.
Several trials addressing these goals are currently in progress and/or are in development by the Kaposi's Sarcoma Working Group. Please check out our Current Studies.